Problems with wholesale inventories made Salix Pharmaceuticals Ltd. an unattractive takeout target to Allergan Inc. last year, but former Allergan suitor Valeant Pharmaceuticals International Inc. doesn’t see the issue as a hindrance and believes it is up for the task of squeezing profits out of the specialty pharma’s gastrointestinal franchises.
With its battle for Allergan firmly in the rearview, Valeant has moved on to acquiring Salix in its largest deal...